Literature DB >> 50433

Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions.

R E Notari, J L DeYoung.   

Abstract

The hydrolytic degradation of 5-azacytidine was studied spectrophotometrically as a function of pH, temperature, and buffer concentration. Loss of drug followed apparent first-order kinetics in the pH region below 3. At pH less than 1,5-azacytosine and 5-azauracil were detected; at higher pH values, drug was lost to products which were essentially nonchromophoric if examined in acidic solutions. The apparent first-order rate constants associated with formation of 5-azacytosine and 5-azauracil from 5-azacytidine are reported. Above pH 2.6, first-order plots for drug degradation are biphasic. Apparent first-order rate constants and coefficients for the biexponential equation are given as a function of pH and buffer concentration. A reaction mechanism consistent with the data is discussed together with problems associated with defining the stability of the drug in aqueous solutions. At 50 degrees, the drug exhibited maximum stability at pH 6.5 in dilute phosphate buffer. Similar solutions were stored at 30 degrees to estimate their useful shelflife. Within 80 min, 6 times 10(-4) M solutions of 5-azacytidine decreased to 90% of original potency based on assumptions related to the proposed mechanisms.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50433     DOI: 10.1002/jps.2600640704

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  25 in total

1.  Analysis of the effect of endogenous viral genes in the Smyth line chicken model for autoimmune vitiligo.

Authors:  G P Sreekumar; J R Smyth; S Ambady; F A Ponce de Leon
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  A robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of 5-azacytidine.

Authors:  Nicole M Anders; Teresia M Wanjiku; Ping He; Nilofer S Azad; Michelle A Rudek
Journal:  Biomed Chromatogr       Date:  2015-08-17       Impact factor: 1.902

3.  Precision DNA demethylation ameliorates disease in lupus-prone mice.

Authors:  Hao Li; Maria G Tsokos; Sean Bickerton; Amir Sharabi; Yi Li; Vaishali R Moulton; Philip Kong; Tarek M Fahmy; George C Tsokos
Journal:  JCI Insight       Date:  2018-08-23

Review 4.  The future of epigenetic therapy in solid tumours--lessons from the past.

Authors:  Nilofer Azad; Cynthia A Zahnow; Charles M Rudin; Stephen B Baylin
Journal:  Nat Rev Clin Oncol       Date:  2013-04-02       Impact factor: 66.675

5.  DNA demethylation induced by 5-azacytidine does not affect fragile X expression.

Authors:  T W Glover; J Coyle-Morris; L Pearce-Birge; C Berger; R M Gemmill
Journal:  Am J Hum Genet       Date:  1986-03       Impact factor: 11.025

Review 6.  Arabinosyl-5-azacytosine: a novel nucleoside entering clinical trials.

Authors:  J L Grem; D D Shoemaker; D F Hoth; S A King; J Plowman; D Zaharko; C K Grieshaber; S D Harrison; J C Cradock; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

7.  Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.

Authors:  Nicole M Anders; Jianyong Liu; Teresia Wanjiku; Hugh Giovinazzo; Jianya Zhou; Ajay Vaghasia; William G Nelson; Srinivasan Yegnasubramanian; Michelle A Rudek
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-03-21       Impact factor: 3.205

8.  Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome.

Authors:  M Thurnher; S Rusconi; E G Berger
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells.

Authors:  P A Jones; S M Taylor
Journal:  Nucleic Acids Res       Date:  1981-06-25       Impact factor: 16.971

10.  Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model.

Authors:  Marcela A Garabalino; Elisa M Heber; Andrea Monti Hughes; Sara J González; Ana J Molinari; Emiliano C C Pozzi; Susana Nievas; Maria E Itoiz; Romina F Aromando; David W Nigg; William Bauer; Verónica A Trivillin; Amanda E Schwint
Journal:  Radiat Environ Biophys       Date:  2013-04-17       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.